EP
FULC icon

Essential Partners’s Fulcrum Therapeutics FULC Stock Holding History

Essential Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.22K Sell
599
-215
-26% -$807 ﹤0.01% 1887
2026
Q2 		$2.98K Buy
814
+813
+81,300% +$4.94K ﹤0.01% 1797
2026
Q1 		$8 Hold
1
– – ﹤0.01% 2843
2025
Q4 		$11 Hold
1
– – ﹤0.01% 2749
2025
Q3 		$9 Buy
+1
New +$7 ﹤0.01% 2659

Other funds holding FULC

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
CP
Castleview Partners Dallas, Texas $228M AUM 13.32% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's FULC Position: Q3 2026 in Review

Essential Partners reduced its Fulcrum Therapeutics (FULC) stake by 26% in Q3 2026, selling an estimated $807 and leaving 599 shares worth $2.22K. The position accounts for ﹤0.01% of the portfolio, ranked #1887.

Essential Partners first reported a position in FULC in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.98K in Q2 2026. 10 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Essential Partners held 599 shares of Fulcrum Therapeutics worth $2.22K as of Q3 2026.
  • Essential Partners sold 215 Fulcrum Therapeutics shares in Q3 2026, an estimated $807.
  • Fulcrum Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1887 holding.
  • Essential Partners first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Essential Partners's Fulcrum Therapeutics position peaked at $2.98K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.